i-SENS, Inc.

KOSDAQ 099190.KQ

i-SENS, Inc. Receivables for the year ending December 31, 2023: USD 57.16 M

i-SENS, Inc. Receivables is USD 57.16 M for the year ending December 31, 2023, a 25.82% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

i-SENS, Inc. Receivables for the year ending December 31, 2022 was USD 45.43 M, a 5.88% change year over year.
i-SENS, Inc. Receivables for the year ending December 31, 2021 was USD 42.90 M, a 14.59% change year over year.
i-SENS, Inc. Receivables for the year ending December 31, 2020 was USD 37.44 M, a -10.33% change year over year.
i-SENS, Inc. Receivables for the year ending December 31, 2019 was USD 41.75 M, a -5.96% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

KOSDAQ: 099190.KQ

i-SENS, Inc.

CEO	Dr. Geun-Sig Cha
IPO Date	Jan. 30, 2013
Location	South Korea
Headquarters	43, Banpo-daero 28-gil
Employees	687
Sector	Consumers Staples
Industries Personal Care Biotechnology Frozen Foods Hardware & Electronics Medical Instruments Non-Alcoholic Beverages Pharmaceuticals Telehealth

Description

i-SENS, Inc. provides diagnostic biosensors in South Korea. The company offers point of care testing devices, such as HbA1c, blood gas, electrolyte, and PT/INR analyzers; CareSens blood glucose monitoring systems; and lancing and other ancillary devices, as well as diabetes management services. It exports its products to approximately 110 countries, including the United States, Japan, and Europe. The company was founded in 2000 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years